Product information and disease descriptionPlace of product in therapyDisease description
Diagnosis
22 evidence topics · 13 sources
Liver biopsy: reference standard for grading and staging, AASLD 2023 practice guidance
“Although liver biopsy assessment remains the reference standard for the grading and staging of NASH, it has important limitations related to risk, cost, and resource utilization. Therefore, liver biopsies for grading and staging of NASH are not consistently performed in clinical practice and should be reserved for specific clinical scenarios (Figure 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Liver biopsy should be considered when NITs suggest significant fibrosis (≥ F2), especially if additional evaluation suggests the presence of “at-risk” NASH (eg, using FAST, MEFIB, MAST, or cT1), NIT assessment is indeterminate, aminotransferases are persistently elevated (> 6 mo), or additional/alternate diagnoses are suspected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Liver biopsy: required for a definite diagnosis of steatohepatitis, EASL-EASD-EASO 2024 guideline
Liver biopsy: only reliable means to diagnose NASH, AGA clinical care pathway
“A liver biopsy is currently the only reliable means to diagnose NASH and is the reference standard for fibrosis staging. However, liver biopsy may not be feasible to obtain in a significant number of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Liver biopsy: reserved to the specialist, ADA Standards of Care 2026
“While liver biopsy remains the gold standard for the diagnosis of MASH, its indication is reserved to the discretion of the specialist within an interprofessional team approach due to high costs and potential for morbidity associated with this procedure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary risk assessment with FIB-4: thresholds, AASLD 2023 practice guidance
“When the fibrosis-4 index (FIB-4) is <1.3, patients can be followed in the primary care setting and reassessed periodically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients older than age 65, a FIB-4 cutoff of > 2.0 should be used. FIB-4 has low accuracy in those under age 35; thus, secondary assessment should be considered in those <35 with increased metabolic risk or elevated liver chemistries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with FIB4 ≥ 1.3, a secondary assessment should be done [preferentially vibration-controlled elastography (VCTE) or Enhanced Liver Fibrosis (ELF) initially] or the patient referred for further risk stratification (if being seen in a nongastroenterology/hepatology setting). Direct referral to gastroenterology/hepatology should be considered in those with aminotransferases persistently (> 6 mo) above normal to exclude other causes of liver disease or when FIB4 > 2.67 due to the increased risk of clinically significant fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, a change in FIB-4 status category from low risk (< 1.3) to intermediate risk (1.3–2.67) to high risk (> 2.67) may be used to assess clinical progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary risk assessment with FIB-4: thresholds and false negatives, EASL-EASD-EASO 2024 guideline
Primary risk assessment with FIB-4: thresholds, AGA clinical care pathway
“Previous studies have shown that FIB-4 score <1.3 (<2.0 in those older than 65 years) can reliably exclude advanced fibrosis in patients with NAFLD, with a negative predictive value of ≥90%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with FIB-4 score >2.67 are at high risk for advanced fibrosis,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The remaining 30%-40% of patients with an FIB-4 test would likely have values in the indeterminate range (ie, 1.3–2.67).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Screening with FIB-4 in type 2 diabetes or prediabetes: ADA Standards of Care 2026
“4.22a Screen adults with type 2 diabetes or with prediabetes, particularly those with obesity or other cardiometabolic risk factors or established cardiovascular disease, for their risk of having or developing cirrhosis related to metabolic dysfunction–associated steatohepatitis (MASH) using a calculated fibrosis-4 index (FIB-4)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“4.23 Adults with type 2 diabetes or prediabetes with a FIB-4 ≥ 1.3 should have additional risk stratification by liver stiffness measurement with transient elastography, or, if unavailable, the enhanced liver fibrosis (ELF) test. B” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A value of <1.3 is considered low risk of having advanced fibrosis (F3–F4) and for developing adverse liver outcomes, while ≥1.3 is considered as having a higher probability of at-risk MASH clinically significant fibrosis (≥F2) and increased risk of adverse liver outcomes. A value of >2.67 confers a high risk of having advanced fibrosis (F3–F4), and referral to the liver specialist is warranted without additional testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In individuals with diabetes ≥65 years of age, higher cutoffs for FIB-4 have been recommended (1.9–2.0 rather than ≥1.3)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aminotransferases: frequently normal in clinically significant fibrosis
“Aminotransferase levels are frequently normal in patients with advanced liver disease due to NASH and should not be used in isolation to exclude the presence of NASH with clinically significant fibrosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A screening strategy relying on elevated plasma aminotransferases >40 units/L would miss most individuals with MASH in these settings, as at-risk MASH with clinically significant fibrosis (≥F2) is frequently observed with plasma aminotransferases below the commonly used cutoff of 40 units/L” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vibration-controlled transient elastography: liver stiffness thresholds, AASLD 2023 practice guidance
“A recent meta-analysis suggested that a VCTE-derived liver stiffness measurement (LSM) <8 kPa can be used to rule out advanced fibrosis, especially if used sequentially after FIB-4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LSMs by VCTE between 8 and 12 kPa may be associated with fibrotic NASH, and LSM > 12 kPa is associated with a high likelihood of advanced fibrosis, although the positive predictive value is low (range: 0.34–0.71).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In identifying patients with cirrhosis, a sequential approach with a FIB-4 > 3.48 and LSM by VCTE ≥ 20 kPa had a specificity of 90%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vibration-controlled transient elastography: liver stiffness thresholds, AGA clinical care pathway
“In a study of 450 consecutive adults who underwent liver biopsy and FibroScan for suspected NAFLD at 7 centers, the Youden cutoff value for F≥F2 was 8.2 kPa.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A value of >12.1 kPa on VCTE indicates that clinically significant fibrosis is likely, with positive predictive values of 76% and 88% in patients seen in diabetes and hepatology clinic populations, respectively, although the positive predictive value can be low in primary care populations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that patients with discordant or indeterminate LSM results (ie, 8.0–12.0 kPa) in primary care and endocrine clinics be referred to hepatology where, like high-risk patients, they might need to undergo either a liver biopsy or MRE for further diagnostic evaluation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vibration-controlled transient elastography and ELF: thresholds in type 2 diabetes or prediabetes, ADA Standards of Care 2026
“An LSM value of <8.0 kPa has a good negative predictive value to exclude advanced fibrosis (≥F3–F4)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If the LSM is ≥8.0 kPa, the risk for advanced fibrosis (≥F3-F4) is higher and such individuals should be referred to the hepatologist” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with ELF ≥9.8 are considered at high risk of having MASH with advanced liver fibrosis (≥F3–F4) and therefore are at risk for adverse liver outcomes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An ELF <9.8 suggests an individual is at low risk of advanced liver fibrosis and may be followed in the nonspecialty clinic with repeat testing in ≥2 years but may need repeat testing more often if ELF is between 9.2 and 9.7.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Enhanced Liver Fibrosis test: thresholds, AASLD 2023 practice guidance
“The ELF panel is a proprietary blood test consisting of three elements involved in matrix turnover: hyaluronic acid, tissue inhibitor of metalloproteinase-1, and N-terminal procollagen III peptide. An ELF score of ≥ 9.8 reliably identifies patients with NAFLD at increased risk of progression to cirrhosis and liver-related clinical events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Note that in patients with confirmed or suspected advanced fibrosis, an ELF ≥ 11.3 is a predictor of future liver-related events and is approved for this purpose; use of other ELF cutoffs in secondary risk assessment is based on expert option.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Magnetic resonance elastography: accuracy and thresholds, AASLD 2023 practice guidance
“MRE is more sensitive than VCTE in the detection of fibrosis stage ≥ 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although MRE is not a first-line approach to risk stratification in a patient with NAFLD, it can be an important tool if clinical uncertainty exists, if there is a need for concomitant cross-sectional imaging, or when other elastography techniques are unavailable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An LSM by MRE ≥ 5 kPa is suggestive of cirrhosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Note that the units for LSM by VCTE and MRE are both kilopascals, but the scales are different.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rule-out and rule-in cut-offs of non-invasive tests for fibrosis and at-risk MASH, EASL-EASD-EASO 2024 guideline
| Non-invasive test | Rule-out cut-off | Rule-in cut-off |
|---|---|---|
| FIB-4 | “F3: 1.3” | “F3: 2.67” |
| ELF | “F3: 7.7” | “F3: 9.8” |
| VCTE liver stiffness | “F3: 8 kPa” | “F3: 12 kPa” |
| MEFIB (MRE combined with FIB-4) | “F2: MRE <3.3 kPa and FIB-4 <1.6” | “F2: MRE ≥3.3 kPa and FIB-4 ≥1.6” |
FibroScan-AST score for at-risk NASH: rule-out and rule-in cut-offs
“The most predictive model combined LSM, CAP, and AST, and was designated FAST (FibroScan-AST).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cutoff for sensitivity (≥0·90) was 0·35 and for specificity (≥0·90) was 0·67 in the derivation cohort” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selection of resmetirom candidates with non-invasive tests: AASLD 2024 guidance update
Selection of semaglutide candidates with non-invasive tests: AASLD 2025 guidance update
Diagnosis rate of noncirrhotic NASH with moderate to advanced fibrosis: US population calculator for resmetirom eligibility
“Published analyses suggest a diagnosis rate of ~ 10% (range 3.3–14.3%) and ~ 16% year-over-year growth in the treatment-eligible population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Estimation of the treatment-eligible population for resmetirom depends importantly on NASH diagnosis rates, which are predicted to be < 15% in the 3 years after drug approval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“First, from additional analysis of NHANES data, it is estimated that 14.3% of prevalent patients with F2/F3 NASH have received a diagnosis of liver disease in a clinical setting (based on survey responses)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of diagnosed NASH: US adults, National Health and Wellness Survey 2016
“Data came from the 2016 National Health and Wellness Survey, a nationally representative patient-reported outcomes survey conducted in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 2016 prevalence of diagnosed NASH among the US adult population was 0.15%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Self-reported liver disease awareness: US adults with MASLD and with liver stiffness 8 to 15 kPa, NHANES 2017 to 2023
“This study utilized the NHANES data cycle 2017–2020 and 2021–2023, a nationally representative survey of the noninstitutionalized U.S. population conducted by the National Center for Health Statistics (NCHS), which included vibration-controlled transient elastography (VCTE) data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with MASLD and LS 8–15 kPa were considered resmetirom-eligible in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Awareness of liver disease among individuals with MASLD remained low, with 5.8% (95% CI: 4.5%–7.2%) pre-pandemic and 6.7% (95% CI: 5.4%–8.1%) late-pandemic reporting awareness (p=0.36). Among those eligible for resmetirom, awareness was 12.1% (95% CI: 5.4%–18.8%) pre-pandemic and 10.3% (95% CI: 6.4%–14.2%) late-pandemic (p=0.63).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Underdiagnosis of at-risk MASH in type 2 diabetes or prediabetes
“Clinicians underestimate the prevalence of at-risk MASH and do not consistently implement appropriate screening strategies in people with prediabetes or type 2 diabetes, thus missing a chance to establish an early diagnosis. This pattern of underdiagnosis is compounded by sparse referral to specialists and inadequate prescription of medications with potential efficacy in MASH” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote